BMO Capital Initiates Coverage On Axsome Therapeutics with Outperform Rating, Announces Price Target of $310

Benzinga Newsdesk www.benzinga.com Positive 59.2%

Neg 0% Neu 0% Pos 59.2%

BMO Capital analyst Malcolm Hoffman initiates coverage on Axsome Therapeutics (NASDAQ:AXSM) with a Outperform rating and announces Price Target of $310.